In This Section
While many scientists in the relatively new field of personalized medicine are busy trying to characterize the molecular basis of various diseases, Amalia M. Issa, PhD, MPH, is leading the way in understanding the real-world implementation and integration of personalized medicine into clinical care and health systems.
Dr. Issa founded The Program in Personalized Medicine & Targeted Therapeutics (P2MT2)™ in 2001 as one of the first centers focused on pharmacogenomics and personalized medicine in order to advance the science and translation of personalized medicine through state-of-the-art research and education.
“The key question that drives our research is what is needed for personalized medicine to be well integrated into clinical practice and effectively incorporated into healthcare delivery and health systems,” she said.
Rapidly occurring advancements in personalized medicine are generating new decision-making issues for healthcare professionals, patients, and/or their families. In particular, personalized medicine technologies and genomic testing provide risk stratification and prognostic information that need to be interpreted and used appropriately within the context of the clinical encounter.
“The question is how do we develop best practices to quantify these and make the necessary trade-offs,” said Dr. Issa, who has developed innovative methods to investigate decision making for personalized medicine applications by patients and providers, including the Patient Preferences for Personalized Medicine Survey© instrument.
“As personalized genomic medicine continues to evolve, it will change healthcare delivery as we currently know it,” said Dr. Issa. “There is no doubt that this field is a game changer for how healthcare is delivered. Our goal is to help get everyone ready and to enable the transformation.”